ID: ALA138746

Max Phase: Preclinical

Molecular Formula: C19H29N5O6

Molecular Weight: 423.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCn1c(=O)c2c(ncn2[C@@H]2O[C@H](C(=O)NC)[C@@H](O)[C@H]2O)n(CCCC)c1=O

Standard InChI:  InChI=1S/C19H29N5O6/c1-4-6-8-22-15-11(17(28)23(19(22)29)9-7-5-2)24(10-21-15)18-13(26)12(25)14(30-18)16(27)20-3/h10,12-14,18,25-26H,4-9H2,1-3H3,(H,20,27)/t12-,13+,14-,18+/m0/s1

Standard InChI Key:  FOUQIXNUUYCGAU-MOROJQBDSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 423.47

Molecular Weight (Monoisotopic): 423.2118

AlogP: -0.67

#Rotatable Bonds: 8

Polar Surface Area: 140.61

Molecular Species: NEUTRAL

HBA: 10

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 11

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.39

CX Basic pKa:

CX LogP: 0.06

CX LogD: 0.06

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.51

Np Likeness Score: -0.14

References

1. Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA..  (2002)  Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.,  45  (20): [PMID:12238926] [10.1021/jm020211+]

2. Baraldi PG, Preti D, Borea PA, Varani K..  (2012)  Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.,  55  (12): [PMID:22468757] [10.1021/jm300087j]

3. Faudone G, Arifi S, Merk D..  (2021)  The Medicinal Chemistry of Caffeine.,  64  (11.0): [PMID:34019396] [10.1021/acs.jmedchem.1c00261]

Source

Source(1):

• Scientific Literature